These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634 [TBL] [Abstract][Full Text] [Related]
7. Current perspectives on the treatment of venous thromboembolism: need for effective, safe and convenient new antithrombotic drugs. O'Shaughnessy DF Int J Clin Pract; 2004 Mar; 58(3):277-84. PubMed ID: 15117096 [TBL] [Abstract][Full Text] [Related]
8. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360 [TBL] [Abstract][Full Text] [Related]
9. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer. Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285 [TBL] [Abstract][Full Text] [Related]
10. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Kearon C; Kahn SR; Agnelli G; Goldhaber S; Raskob GE; Comerota AJ Chest; 2008 Jun; 133(6 Suppl):454S-545S. PubMed ID: 18574272 [TBL] [Abstract][Full Text] [Related]
11. New-generation anticoagulants: the low molecular weight heparins. Hovanessian HC Ann Emerg Med; 1999 Dec; 34(6):768-79. PubMed ID: 10577408 [TBL] [Abstract][Full Text] [Related]
12. Direct oral anticoagulants and heparins: laboratory values and pitfalls in 'bridging therapy'. Eller T; Flieder T; Fox V; Gripp T; Dittrich M; Kuhn J; Alban S; Knabbe C; Birschmann I Eur J Cardiothorac Surg; 2017 Apr; 51(4):624-632. PubMed ID: 28043992 [TBL] [Abstract][Full Text] [Related]
14. Thrombolytic therapy for submassive pulmonary embolism. Lankeit M; Konstantinides S Best Pract Res Clin Haematol; 2012 Sep; 25(3):379-89. PubMed ID: 22959553 [TBL] [Abstract][Full Text] [Related]
15. The low molecular weight heparin, tinzaparin, in thrombosis and beyond. Mousa SA Cardiovasc Drug Rev; 2002; 20(3):199-216. PubMed ID: 12397367 [TBL] [Abstract][Full Text] [Related]
16. Suboptimal management of unfractionated heparin compared with low-molecular-weight heparin in the management of pulmonary embolism. Khor YH; Smith R; McDonald CF Intern Med J; 2014 Apr; 44(4):339-44. PubMed ID: 24877250 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. Büller HR; Davidson BL; Decousus H; Gallus A; Gent M; Piovella F; Prins MH; Raskob G; van den Berg-Segers AE; Cariou R; Leeuwenkamp O; Lensing AW; N Engl J Med; 2003 Oct; 349(18):1695-702. PubMed ID: 14585937 [TBL] [Abstract][Full Text] [Related]
18. Blocking inhibition of prothrombinase by tissue factor pathway inhibitor alpha: a procoagulant property of heparins. Wood JP; Baumann Kreuziger LM; Desai UR; Mast AE Br J Haematol; 2016 Oct; 175(1):123-32. PubMed ID: 27301751 [TBL] [Abstract][Full Text] [Related]
19. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Hillis C; Crowther MA Thromb Haemost; 2015 Jun; 113(6):1193-202. PubMed ID: 25948149 [TBL] [Abstract][Full Text] [Related]
20. Inverse relationship of bleeding risk with clot burden during pulmonary embolism treatment with LMW heparin. Wang C; Zhai Z; Yang Y; Cheng Z; Ying K; Liang L; Dai H; Huang K; Lu W; Zhang Z; Cheng X; Shen YH; Davidson BL; Clin Respir J; 2016 Sep; 10(5):596-605. PubMed ID: 25619125 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]